🔴 Neurosense Therapeutics is trading 18.3% down in after-hours trading — no specific cause established

Neurosense Therapeutics is trading at $2.85, down 18.34% in after-hours trading; available evidence does not establish a specific cause.

• Nasdaq appeal hearing is set for November 10; shares are expected to keep trading while the appeal is pending.
• The remaining listing issue is Nasdaq’s $35 million minimum market-value requirement. The company plans to present a compliance plan, but an exception is not assured.
• The release cited a planned December 2026 Health Canada submission and a Q1 2027 grant-funding decision, not linked to the decline.